肺癌的抗血管生成治疗：聚焦血管内皮生长因子通路。
Antiangiogenic therapy in lung cancer: focus on vascular endothelial growth factor pathway.
机构信息
Department of Medical Oncology, Mater Misericordiae University Hospital, Eccles St, Dublin 7, Ireland.
出版信息
Exp Biol Med (Maywood). 2010 Jan;235(1):3-9. doi: 10.1258/ebm.2009.009191.
Abstract
Lung cancer (LC) is a leading cause of death worldwide. Recent advances in chemotherapeutic agents have not yielded any significant improvement in the prognosis of patients with LC. The five-year survival rate for all combined disease stages remains about 15%. For this reason, new therapies such as those that inhibit tumor angiogenesis or block activity of growth factor receptors are of special interest in this group of patients. In this review we will summarize the most recent clinical data on biologic therapies that inhibit tumor angiogenesis in LC, focusing on those that are most clinically relevant.
摘要
肺癌（LC）是全球范围内主要的致死病因。化疗药物的最新进展并未显著改善 LC 患者的预后。所有合并疾病阶段的五年生存率仍保持在约 15%。因此，在这群患者中，诸如抑制肿瘤血管生成或阻断生长因子受体活性的新疗法特别受到关注。在本综述中，我们将总结 LC 中抑制肿瘤血管生成的生物疗法的最新临床数据，重点关注那些最具临床相关性的药物。
相似文献
1
Antiangiogenic therapy in lung cancer: focus on vascular endothelial growth factor pathway.肺癌的抗血管生成治疗：聚焦血管内皮生长因子通路。
Exp Biol Med (Maywood). 2010 Jan;235(1):3-9. doi: 10.1258/ebm.2009.009191.
2
Emerging data with antiangiogenic therapies in early and advanced non-small-cell lung cancer.早期和晚期非小细胞肺癌抗血管生成治疗的新数据。
Clin Lung Cancer. 2009 Mar;10 Suppl 1(Suppl 1):S7-16. doi: 10.3816/CLC.2009.s.002.
3
Drug insight: VEGF as a therapeutic target for breast cancer.药物洞察：血管内皮生长因子作为乳腺癌的治疗靶点
Nat Clin Pract Oncol. 2007 Mar;4(3):181-9. doi: 10.1038/ncponc0740.
4
Antiangiogenic drugs in non-small cell lung cancer treatment.非小细胞肺癌治疗中的抗血管生成药物
Curr Opin Oncol. 2006 Mar;18(2):151-5. doi: 10.1097/01.cco.0000208788.99570.0e.
5
Combined inhibition of vascular endothelial growth factor and epidermal growth factor signaling in non-small-cell lung cancer therapy.在非小细胞肺癌治疗中联合抑制血管内皮生长因子和表皮生长因子信号传导
Clin Lung Cancer. 2009 Mar;10 Suppl 1:S17-23. doi: 10.3816/CLC.2009.s.003.
6
[Targeted therapies. New hopes, new challenges].[靶向治疗。新希望，新挑战]
Rev Mal Respir. 2008 Jun;25(6):661-2. doi: 10.1016/s0761-8425(08)73795-1.
7
Efficacy and safety of angiogenesis inhibitors in advanced non-small cell lung cancer: a systematic review and meta-analysis.血管生成抑制剂在晚期非小细胞肺癌中的疗效与安全性：一项系统评价与荟萃分析
J Cancer Res Clin Oncol. 2015 May;141(5):909-21. doi: 10.1007/s00432-014-1862-5. Epub 2014 Nov 6.
8
Targeted therapies in non-small cell lung cancer: proven concepts and unfulfilled promises.非小细胞肺癌的靶向治疗：已证实的概念与未兑现的承诺
Curr Cancer Drug Targets. 2006 Jun;6(4):271-94. doi: 10.2174/156800906777441780.
9
The role of anti-angiogenesis in non-small-cell lung cancer: an update.抗血管生成在非小细胞肺癌中的作用：最新进展
Curr Oncol Rep. 2015 Jun;17(6):26. doi: 10.1007/s11912-015-0448-y.
10
Circulating endothelial and endothelial progenitor cells in non-small-cell lung cancer.非小细胞肺癌中的循环内皮细胞和内皮祖细胞。
Clin Transl Oncol. 2010 Aug;12(8):521-5. doi: 10.1007/s12094-010-0549-x.
引用本文的文献
1
Imaging the Rewired Metabolism in Lung Cancer in Relation to Immune Therapy.肺癌中与免疫治疗相关的代谢重塑成像
Front Oncol. 2022 Jan 7;11:786089. doi: 10.3389/fonc.2021.786089. eCollection 2021.
2
Uncovering the Anti-Lung-Cancer Mechanisms of the Herbal Drug FDY2004 by Network Pharmacology.基于网络药理学揭示中药FDY2004的抗肺癌机制
Evid Based Complement Alternat Med. 2021 Feb 4;2021:6644018. doi: 10.1155/2021/6644018. eCollection 2021.
3
Sorsby Fundus Dystrophy Mutation in Tissue Inhibitor of Metalloproteinase 3 (TIMP3) promotes Choroidal Neovascularization via a Fibroblast Growth Factor-dependent Mechanism.Sorsby 型眼底营养不良突变组织金属蛋白酶抑制剂 3（TIMP3）通过成纤维细胞生长因子依赖机制促进脉络膜新生血管形成。
Sci Rep. 2019 Nov 22;9(1):17429. doi: 10.1038/s41598-019-53433-6.
4
Increased Wnt5a in squamous cell lung carcinoma inhibits endothelial cell motility.鳞状细胞肺癌中Wnt5a增加会抑制内皮细胞运动。
BMC Cancer. 2016 Nov 23;16(1):915. doi: 10.1186/s12885-016-2943-4.
5
Assessing Tumor Response to Treatment in Patients with Lung Cancer Using Dynamic Contrast-Enhanced CT.使用动态对比增强 CT 评估肺癌患者的肿瘤治疗反应。
Diagnostics (Basel). 2016 Jul 21;6(3):28. doi: 10.3390/diagnostics6030028.
6
Diallyl trisulfide inhibits migration, invasion and angiogenesis of human colon cancer HT-29 cells and umbilical vein endothelial cells, and suppresses murine xenograft tumour growth.二烯丙基三硫化物抑制人结肠癌HT - 29细胞和人脐静脉内皮细胞的迁移、侵袭和血管生成，并抑制小鼠异种移植瘤的生长。
J Cell Mol Med. 2015 Feb;19(2):474-84. doi: 10.1111/jcmm.12486. Epub 2014 Nov 17.
7
Dopamine D2 receptor agonists inhibit lung cancer progression by reducing angiogenesis and tumor infiltrating myeloid derived suppressor cells.多巴胺 D2 受体激动剂通过减少血管生成和肿瘤浸润性髓源性抑制细胞来抑制肺癌进展。
Mol Oncol. 2015 Jan;9(1):270-81. doi: 10.1016/j.molonc.2014.08.008. Epub 2014 Aug 30.
8
A phase II multicentre study of ziv-aflibercept in combination with cisplatin and pemetrexed in patients with previously untreated advanced/metastatic non-squamous non-small cell lung cancer.一项评估在先前未经治疗的晚期/转移性非鳞状非小细胞肺癌患者中联合使用 ziv-aflibercept、顺铂和培美曲塞的 II 期多中心研究。
Br J Cancer. 2014 Feb 4;110(3):602-8. doi: 10.1038/bjc.2013.735. Epub 2013 Nov 28.
9
Targeting angiogenesis and the tumor microenvironment.靶向血管生成与肿瘤微环境。
Surg Oncol Clin N Am. 2013 Oct;22(4):629-39. doi: 10.1016/j.soc.2013.06.002. Epub 2013 Jul 26.
10
The role of vascular endothelial growth factor in the pathogenesis, diagnosis and treatment of malignant pleural effusion.血管内皮生长因子在恶性胸腔积液发病机制、诊断和治疗中的作用。
Curr Oncol Rep. 2013 Jun;15(3):207-16. doi: 10.1007/s11912-013-0315-7.
本文引用的文献
1
Biological mechanisms of bevacizumab-associated adverse events.贝伐单抗相关不良事件的生物学机制。
Expert Rev Anticancer Ther. 2009 Jul;9(7):999-1007. doi: 10.1586/era.09.68.
2
Recent developments of targeted therapies in the treatment of non-small cell lung cancer.非小细胞肺癌治疗中靶向疗法的最新进展。
Curr Drug Discov Technol. 2009 Jun;6(2):91-102. doi: 10.2174/157016309788488339.
3
Improvement of antiangiogenic cancer therapy by understanding the mechanisms of angiogenic factor interplay and drug resistance.通过了解血管生成因子相互作用和耐药性的机制来改善抗血管生成癌症治疗。
Semin Cancer Biol. 2009 Oct;19(5):338-43. doi: 10.1016/j.semcancer.2009.05.001. Epub 2009 May 27.
4
Phase III trial of cisplatin plus gemcitabine with either placebo or bevacizumab as first-line therapy for nonsquamous non-small-cell lung cancer: AVAil.顺铂联合吉西他滨加安慰剂或贝伐单抗作为非鳞状非小细胞肺癌一线治疗的III期试验：AVAil研究
J Clin Oncol. 2009 Mar 10;27(8):1227-34. doi: 10.1200/JCO.2007.14.5466. Epub 2009 Feb 2.
5
Osteonecrosis of the jaw related to bevacizumab.与贝伐单抗相关的颌骨骨坏死
J Clin Oncol. 2008 Aug 20;26(24):4037-8. doi: 10.1200/JCO.2007.15.5424.
6
Aflibercept: AVE 0005, AVE 005, AVE0005, VEGF Trap - Regeneron, VEGF Trap (R1R2), VEGF Trap-Eye.阿柏西普：AVE 0005、AVE 005、AVE0005、VEGF Trap - 再生元、VEGF Trap（R1R2）、VEGF Trap - 眼用制剂
Drugs R D. 2008;9(4):261-9. doi: 10.2165/00126839-200809040-00006.
7
Second-generation epidermal growth factor receptor tyrosine kinase inhibitors in non-small cell lung cancer.第二代表皮生长因子受体酪氨酸激酶抑制剂在非小细胞肺癌中的应用
J Thorac Oncol. 2008 Jun;3(6 Suppl 2):S146-9. doi: 10.1097/JTO.0b013e318174e96e.
8
Dual targeting of the vascular endothelial growth factor receptor and epidermal growth factor receptor pathways with vandetinib (ZD6474) in patients with advanced or metastatic non-small cell lung cancer.凡德他尼（ZD6474）对晚期或转移性非小细胞肺癌患者的血管内皮生长因子受体和表皮生长因子受体途径进行双重靶向治疗。
J Thorac Oncol. 2008 Jun;3(6 Suppl 2):S128-30. doi: 10.1097/JTO.0b013e318174e95a.
9
Summary statement novel agents in the treatment of lung cancer: Fifth Cambridge Conference assessing opportunities for combination therapy.肺癌治疗中的新型药物：第五届剑桥会议评估联合治疗的机会总结声明
J Thorac Oncol. 2008 Jun;3(6 Suppl 2):S107-12. doi: 10.1097/JTO.0b013e318174e9d3.
10
Outcomes for elderly, advanced-stage non small-cell lung cancer patients treated with bevacizumab in combination with carboplatin and paclitaxel: analysis of Eastern Cooperative Oncology Group Trial 4599.贝伐单抗联合卡铂和紫杉醇治疗老年晚期非小细胞肺癌患者的疗效：东部肿瘤协作组4599试验分析
J Clin Oncol. 2008 Jan 1;26(1):60-5. doi: 10.1200/JCO.2007.13.1144.
Zotero 插件